OPTIMIZATION OF BIOLOGICAL THERAPY IN PATIENTS WITH ULCERATIVE COLITIS (CASE REPORT)

Cover Page

Cite item

Full Text

Abstract

Now in Russia registered two biological drugs for the treatment of UC is infliximab and golimumab. The largest experience with the use of infliximab (IFX) shows that, despite the high efficiency, in some patients the IBD (20-30%) will develop acquired secondary loss of response to the drug. The development of secondary loss of anti-cytokine therapy is influenced by the following causes - irregular administration of the drug, monotherapy with monoclonal antibodies, initial high levels of TNF-α and low albumin, the presence of antibodies to the drug, activation of opportunistic infections, and changes in pathogenesis of the disease. The appearance at present in the arsenal of gastroenterologists of golimumab (GLM) has expanded the possibilities of treatment of patients with UC in the case of secondary loss of response to therapy with anti-TNF-α or the development of adverse events on IFX. This clinical case shows that after discontinuation IFX, there is a risk of recurrence of the disease, which according to the literature is 50 %. The example also demonstrated that GLM is well tolerated in patients who develop adverse events on IFX in the form of anaphylaxis. This is because GLM are fully human inhibitor of TNF-α. Golimumab is a new, effective inhibitor of TNF-α, which may help to optimize therapy in UC.

About the authors

O V Knyazev

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

Email: oleg7@bk.ru
д.м.н, заведующий отделением воспалительных заболеваний кишечника ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

A V Kagramanova

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

к.м.н., старший научный сотрудник отделения воспалительных заболеваний кишечника ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

N A Fadeeva

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

к.м.н., старший научный сотрудник отделения воспалительных заболеваний кишечника ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

M V Kirova

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

к.м.н., научный сотрудник отделения внутрипросветной эндоскопии ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

N V Orlova

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

заведующая отделением рентгенологии ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

A I Parfenov

ГБУЗ Московский клинический научно-практический центр Департамента здравоохранения г.Москвы

Email: asfold@mail.ru
профессор, заведующий отделом патологии кишечника ГБУЗ МКНЦ ДЗМ Москва, Шоссе Энтузиастов, 86

O N Boldyreva

ГБУЗ МКНЦ ДЗМ

к.м.н., младший научный сотрудник отделения воспалительных заболеваний кишечника ГБУЗ МКНЦ ДЗМ

References

  1. Carlos Taxonera, David Olivares, Juan L Mendoza, et al. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014 July 21; 20(27): 9170-77.
  2. Philippe Hiroz, Stephan R. Vavricka, Nicolas Fournier, et al. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scandinavian Journal of Gastroenterology, October 2014, Vol. 49, No. 10 : Pages 1207-18.
  3. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009;104:760-7
  4. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review.Am J Gastroenterol 2011;106:674-84.
  5. T. Billiert, P. Rutgeerts et al. Targeting TNF-a for the treatment of inflammatory bowel disease. Expert Opin. Biol. Ther. 2014;14(1):75-101. S. Ben-Horin et al. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmunity reviews. 2014;13:24-30.
  6. M. Giganti, P.M. Beer, N. Lemanski, et al. Adverse events after intravitreal Infliximab (Remicade). Retina. 2010. Vol. 30. P. 71-80.
  7. Vincent F.B. et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-178.
  8. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007; 25:40-46.
  9. Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:R105.
  10. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305: 1460-68.
  11. Plasencia C, Pascual-Salcedo D, Bonilla G, Villalba A, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012 May 6.
  12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601-608.
  13. Karmiris K, Paintaund G, Noman M, Magdelaine-Beuzelin C, et al. Influence of trough serum levels and immumogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628-40.
  14. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
  15. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Jul;34(1):51-8.
  16. Wagner, EULAR 2002 Poster, Wagner, DDW 2002 Poster, Data on File, Centocor, Inc.
  17. О.В. Князев, А.И.Парфенов, И.Н. Ручкина, А.Г. Коноплянников, В.Н. Дроздов, В.Э. Сагынбаева, Т.И. Ивкина. Новые возможности преодоления вторичной неэффективности антицитокиновой терапии у больных воспалительными заболеваниями кишечника. Терапевтический архив, Т.№ 85, 2013; №2: стр. 57-60.
  18. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor. MAbs. 2010 Jul-Aug;2(4):428-39. Epub 2010 Jul 1.
  19. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142:63-70.
  20. Zampeli E, Gizis M, Siakavellas SI, Bamias G. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):293-303.
  21. Lonberg N. Human antibodies from transgenic animals. Nature Biotechnology 2005, v.23, p.1117-25.

Copyright (c) 2015 Knyazev O.V., Kagramanova A.V., Fadeeva N.A., Kirova M.V., Orlova N.V., Parfenov A.I., Boldyreva O.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies